Table 1 Patient and clinical characteristics, stratified by estrogen receptor (ER) status.
CBCS | METABRIC | |||
|---|---|---|---|---|
ER positive N = 2131 | ER negative N = 1067 | ER positive N = 1028 | ER negative N = 303 | |
Median follow-up, years (range)a | 18.1 (0.2–20.0) | 18.0 (0.5–20) | 10.0 (0.0–20.0) | 7.3 (0.1–20.0) |
Median age, years (range) | 51 (23–74) | 48 (24–74) | 63 (26–92) | 53 (22–96) |
Postmenopausal | 1211 (56.8) | 516 (48.4) | 845 (82.2) | 178 (58.7) |
Stage | ||||
0/I | 968 (45.4) | 336 (31.5) | 369 (35.9) | 79 (26.1) |
II | 928 (43.5) | 564 (52.9) | 590 (57.4) | 181 (59.7) |
III | 235 (11.0) | 167 (15.7) | 68 (6.6) | 43 (14.2) |
Missing | 0 | 0 | 1 | 0 |
Grade | ||||
1 | 647 (31.6) | 69 (6.5) | 109 (10.6) | 4 (1.3) |
2 | 896 (42.0) | 183 (17.2) | 491 (47.8) | 28 (9.2) |
3 | 561 (26.3) | 815 (76.4) | 428 (41.6) | 271 (89.4) |
Positive node status | 810 (38.0) | 419 (39.3) | 463 (45.0) | 163 (53.8) |
Tumor size >2 cm | 901 (42.3) | 625 (58.6) | 550 (53.5) | 183 (60.4) |
RNA-based TP53 status | ||||
Wildtype-like | 1038 (75.3) | 98 (14.1) | 735 (71.5) | 23 (7.6) |
Mutant-like | 340 (24.7) | 598 (85.9) | 293 (28.5) | 280 (92.4) |
Missing | 753 | 371 | 0 | 0 |
DNA-based TP53 status | ||||
Wildtype | 258 (74.6) | 85 (35.3) | 775 (77.9) | 54 (18.0) |
Mutant | 88 (25.4) | 156 (64.7) | 220 (22.1) | 246 (82.0) |
Missing | 1785 | 826 | 33 | 3 |
IHC-based TP53 status | ||||
Wildtype-like | 1531 (76.7) | 473 (49.8) | 505 (84.4) | 92 (53.5) |
Mutant-like | 465 (23.3) | 477 (50.2) | 93 (15.6) | 80 (46.5) |
Missing | 135 | 117 | 430 | 131 |
PAM50 subtype | ||||
Luminal A | 885 (64.2) | 65 (9.3) | 498 (48.6) | 11 (3.6) |
Luminal B | 288 (20.9) | 22 (3.2) | 325 (31.7) | 7 (2.3) |
HER2-enriched | 67 (4.9) | 1.08 (15.5) | 61 (6.0) | 88 (29.0) |
Basal-like | 97 (7.0) | 465 (66.8) | 31 (3.0) | 179 (59.1) |
Normal-like | 41 (3.0) | 36 (5.2) | 110 (10.7) | 18 (5.9) |
Missing | 753 | 371 | 3 | 0 |
